

In response to the Advisory Actions of April 14, 2004 and March 15, 2004 in the above-identified application, please amend the application as follows:

IN THE SPECIFICATION

Page 1, lines 18-19, please insert the following:

X₁, X₂, X₃, X₄, same or different, are a group chosen among:

-CONR-, -NRCO-, -CH₂-NR-, -NR-CH₂- where R is H, C₁₋₃ alkyl, or benzyl;

Page 1, lines 22-27, please insert the following:

-(CH₂)_r Ar where r is 0, 1 or 2 and Ar is an aromatic group chosen among benzene, naphthalene, thiophene, benzothiophene, pyridine, quinoline, indole, furan, benzofuran, thiazole, benzothiazole, imidazole, benzoimidazole, possibly substituted with up to 2 substituents chosen among C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₁₋₃ alkyloxy [and], C₂₋₄ amino-alkyloxy, halogen, OH, NH₂, CN, and NR₆R₇, where R₆ and R₇, are the same or different, and are H or C₁₋₃ alkyl,

Page 1, lines 29-32, please insert the following:

-(CH₂)_rAr₁ where r is 0, 1, or 2 and Ar₁ is an aromatic group chosen among: ben[e]zene, naphthalene, thiophene, benzothiophene, pyridine, quinoline, indole, furan, benzofuran, thiazole, benzothiazole, imidazole, benzoimidazole, possibly substituted with up to 2 groups chosen among: C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₁₋₃ alkyloxy, C₂₋₄ amino-alkyloxy, halogens, OH, NH₂, CN, and NR₆R₇, where R₆ and R₇ are the same or different, and are H or C₁₋₃ alkyl;

At page 5, lines 15-20, please insert:

R₉ is a group chosen among: 4-tetrahydropyranyl, ~~4-tetraiodothiopyranyl~~

4-tetrahydrothiopyranyl, ~~1-oxo-4-tetraiodothiopyran-4-yl~~

1-oxotetrahydrothiopyran-4-yl, 1,1 dioxo-tetrahydrothiopyran-4-yl, N-methyl-4-piperidinyl, N-methanesulfonyl-4-piperidinyl, N-aminosulfonyl-4-piperidinyl, or R₈ and R₉ together with the N atom to which they are linked represent N-methyl-piperazinyl, N-acetyl-piperazinyl, piperazinyl, N-methanesulfonyl-piperazinyl.

At page 6, lines 13-18, please insert:

xii) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-CF₃)₃}-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

xiii) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Ala(4-pyridyl)-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

xiv) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Ala(3-pyridyl)-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

Page 7, lines 1-5, please insert:

Among the compounds of formula (I) wherein R, R[1]₁, R[2]₂, R[3]₃, f, m are as hereabove defined preferred are also those wherein:

R₄ represents a group NR₈R₉, where R₈ is H and R[9]₉ is chosen among:

methanesulfonyl, tosyl, a group (CH[2]₂)[g]_g-R₁₀ wherein g is 1[,] or 2 and R₁₀ is chosen among: morpholine, furan, or CN.

Page 7, lines 23-29, please insert:

Another preferred selection of the compound of formula (I) wherein R, R[1]₁, R[2]₂, R[3]₃, f, m are as previously defined, those wherein:

R[4]₄ represents a group -N(R₁₁)CO(CH₂)_h-R₁₂ wherein R₁₁ is H, h is 0 or 1, and R[12]₁₂ is chosen among: 1-tetrazolyl, 5-mercapto-tetrazol-1-yl, 1-triazolyl, furanyl,

thiophenyl, morpholine, 4-hydroxy-piperidine, 4-carboxyamido-piperidine, 3-hydroxy-pyrrolidine,
2-hydroxymethylpyrrolidine, 4-methyl-piperazine, 4-aminosulfonyl-piperazine, 1-oxo-thiomorpholine, 4-hydroxy-cyclohexan-1-yl-amino.

At page 9, lines 7-8, please insert:

Another preferred selection of compounds of formula (I) wherein R, R[1]₁, R[2]₂, R[3]₃, f, m are as above defined are those wherein:

At page 9, lines 9-10, please insert:

R[4]₄ is a group COR₁₃ where R₁₃ is a group chosen among: morpholine and 4-(hydroxyethyloxyethyl)-piperazine.

At page 10, lines 26-31, please insert:

EXAMPLE 1: cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein X₁ = X₂ = X[3]₃ = X₄ = -CO-NH-; R₁ = -CH₂-(indol-3-yl); R₂ = R₃ = -CH₂-C₆H₅; R[4]₄ = (4-tetrahydropyranyl)amino; m = 0, f = 1; the carbon atoms C-R₁ and C-R₂ have configuration S, while C-R₃ and C-R₄ have configuration R).

At page 11, lines 2-5, please insert:

(compound of formula (I) wherein: X₁ = X₂ = X[3]₃ = X₄ = -CO-NH-;

R₁ = -CH₂-(indol-3-yl); R₂ = R₃ = -CH₂-C₆H₅; R₄ = -NH₂; m = 0, f = 1; the carbon atoms C-R₁ and C-R₂ have configuration S, while C-R₃ and C-R₄ have configuration R) is used. The compound A is prepared as follows:

At page 11, lines 24-30, please insert:

c) Synthesis of Boc-Trp-Phe-[(R)-NH-CH(CH₂)₂-C₆H₅)-CH₂-NH-Z]

To a solution of Boc-Trp-Phe-OH (1.19 g, 2.63 mmol) in anhydrous DMF (10 ml) (R)-1-benzyl-2-(benzyloxycarbonylamino)ethylamine (750 mg), PyBOP (1.37 g) and DIEA (0.9 ml) were added under nitrogen. The reaction mixture was left under stirring for a night at room temperature, added with AcOEt (80 ml), washed with HCl 1N (3 x 30 ml), Na₂CO₃ 5% (3 x 30 ml) and H₂O (30 ml). The organic phase was evaporated under vacuum at 30°C, giving 1.8 g of ivory colored solid residue.

At page 14, lines 9-13, please insert:

EXAMPLE 2: cyclo{Suc[1-(S)-(4-tetrahydropyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula (I) wherein C-R[4]₄ has S configuration, R[4]₄ is (4-tetrahydropyranyl)amino and the other substituents are as described for Compound A).

At page 14, lines 18-23, please insert:

EXAMPLE 3: cyclo{Suc[1-(R)-(1-methyl-piperidin-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein R[4]₄ is (1-methyl-piperidin-4-yl)amino and the other substituents are as described for Compound A).

The compound is prepared as in example 1 but using as reagent 1-methyl-4-piperidone.

At page 15, lines 2-6, please insert:

(compound of formula I wherein R[4]₄ is (4-tetrahydrothiopyranyl)amino and the other substituents are as described for compound A).

The compound is prepared according to Example 1 but using as reagent tetrahydrothiopyran-4-one.

At page 15, lines 7-11, please insert:

EXAMPLE 5: cyclo{Suc[1-(R)-(1-oxo-tetrahydrothiopyran-4-yl)amino]-Trp-Phe-[(R)NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein R[4]₄ is (1-oxo-4-tetrahydrothiopyranyl)amino and the other substituents are the same of Compound A).

At page 15, lines 16-20, please insert:

EXAMPLE 6: cyclo{Suc[1-(R)-(1,1-dioxo-tetrahydrothiopyran-4-yl)amino]-Trp-Phe[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein R[4]₄ is (1,1-dioxo-4-tetrahydrothiopyranil)amino and the other substituents are the same of Compound A).

At page 15, lines 25-29, please insert:

EXAMPLE 7: cyclo{Suc[1-(R)-N-methyl-N-(4-tetrahydropyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein R[4]₄ is N-methyl-N-(4-tetrahydropyranyl)amino and the other substituents are the same of Compound A).

At page 16, lines 8-12, please insert:

EXAMPLE 8: cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Tyr-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein [cui] R₂ = 4-hydroxybenzyl, R[4]₄ = (4-tetrahydropyranyl)amino and the other substituents are as defined for Compound A).

At page 16, lines 17-21, please insert:

EXAMPLE 9: cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-F)-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein [cui] R₂ =4-fluorobenzyl, R[4]₄

=(4-tetrahydropyranyl)amino and the other substituents are as defined for Compound A).

At page 16, lines 26-30, please insert:

EXAMPLE 10: cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(3,5-F)-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein [cui] R₂ = 3,5-difluorobenzyl, R[4]₄

=(4-tetrahydropyranyl)amino and the other substituents are as defined for Compound A).

At page 17, lines 5-14, please insert:

EXAMPLE 11: cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-CN)-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

To 377 mg of Boc-(S)-4-ciano-phenylalanine, solved in 8 ml of DMF, HOBt (470 mg),

EDCI.HCl (330 mg) and 630 mg of (R)-1-benzyl-2-(N-

fluorenylmethyloxycarbonylamino)ethylamina trifluoroacetate (prepared according to

Example 1(b)), solved in 8 ml of DMF are added in the given order. DIEA (0.38 ml) is

added drop by drop maintaining under stirring for 3 h. The solution is dried and the

residue is treated with citric acid 105 and water; the precipitated solid is filtered, washed

with water, NaHCO₃ 5%, water and dried. The obtained solid (790 mg) is suspended

in dichlorometane (6.5 ml).

At page 18, lines 26-29, please insert:

EXAMPLE 12: cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-CF₃)₃}-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of formula I wherein R₂ = (4-trifluoromethyl)benzyl, R[4]₄

=(4-tetrahydropyranyl)amino and the other substituents are as in Compound A.

At page 19, lines 3-9, please insert:

EXAMPLE 13: cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Ala(4-pyridyl)-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of formula I wherein R₂ = 4-pyridylmethyl, R[4]₄

=(4-tetrahydropyranyl)amino and the other substituents are as in Compound A.

At page 19, lines 11-14, please insert:

EXAMPLE 14: cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Ala(3-pyridyl)-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein R₂ = 3-pyridylmethyl, R[4]₄ =

(4-tetrahydropyranyl) and the other substituents are as in Compound A.

At page 19, lines 19-24, please insert:

EXAMPLE 15: cyclo{Suc[1-(R)-(1-methylsulfonyl-piperidin-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of formula I wherein R[4]₄ = (1-methylsulfonyl)piperidin-4-yl)amino and the other substituents are as in Compound A).

At page 19, lines 27-30, please insert:

EXAMPLE 16: cyclo{Suc[1-(R)-(1-aminosulfonyl-piperidin-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein $R[4]_4 = (1\text{-aminosulfonyl})\text{piperidin-4-yl}$)amino and the other substituents are as in Compound A).

At page 20, lines 5-8, please insert:

EXAMPLE 17: $\text{cyclo}\{\text{Suc}[1\text{-(R)-(piperazin-1-yl)}]\text{-Trp-Phe-}[(\text{R})\text{-NH-CH(CH}_2\text{-C}_6\text{H}_5\text{)-CH}_2\text{NH}]\}$

(compound of formula I wherein $R[4]_4 = \text{piperazin-1-yl}$ and the other substituents are as in Compound A).

At page 20, lines 20-23, please insert:

EXAMPLE 18: $\text{cyclo}\{\text{Suc}[1\text{-(R)-4-methyl-piperazin-1-yl}]\text{-Trp-Phe-}[(\text{R})\text{-NH-CH(CH}_2\text{-C}_6\text{H}_5\text{)-CH}_2\text{NH}]\}$

(compound of formula I wherein $R[4]_4 = 4\text{-methyl-piperazin-1-yl}$ and the other substituents are as described in Compound A)

At page 21, lines 2-5, please insert:

EXAMPLE 19: $\text{cyclo}\{\text{Suc}[1\text{-(R)-4-acetyl-piperazin-1-yl}]\text{-Trp-Phe-}[(\text{R})\text{-NH-CH(CH}_2\text{-C}_6\text{H}_5\text{)-CH}_2\text{NH}]\}$

(compound of general formula I wherein $R[4]_4 = 4\text{-acetyl-piperazin-1-yl}$ and the other substituents are as described in Compound A)

At page 21, lines 15-18, please insert:

EXAMPLE 20: $\text{cyclo}\{\text{Suc}[1\text{-(R)-(4-methanesulfonyl-piperazin-1-yl)}]\text{-Trp-Phe-}[(\text{R})\text{-NH-CH(CH}_2\text{-C}_6\text{H}_5\text{)-CH}_2\text{NH}]\}$

(compound of general formula I wherein $R[4]_4 = 4\text{-methanesulfonyl-piperazin-1-yl}$ and the other substituents are as described in Compound A).

At page 21, lines 28-31, please insert:

EXAMPLE 21: cyclo{-Suc[1-(S)-methanesulfonylamino]-Trp-Phe-[(R)-NH-CH(CH₂C₆H₅)-CH₂-NH]}

(compound of general formula I wherein C-R[4]₄ has S-configuration, R[4]₄ is methanesulfonylamino and the other substituents are as described in compound A)

At page 22, lines 1-8, please insert:

To a solution of 60 mg of the isomer of Compound A having S-configuration at the C-R[4]₄, prepared as described in Example 1(a)-1(h), in 1 ml DMF, at 0°C, 24 ml of N-methylmorpholine and 10 ml of methanesulfonylchloride are added; the solution is left under stirring for 2 and half h. The reaction mixture is concentrated under vacuum, diluted with ethylacetate and washed with an aqueous solution of citric acid (10%), water, saturated solution of NaHCO₃ and water in the given order. After drying on Na₂SO₄ and evaporation of the solvent the product is isolated by preparative HPLC.

At page 22, lines 16-19, please insert:

EXAMPLE 22: cyclo{Suc[1-(R)-methanesulfonylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein R[4]₄ is methanesulfonylamino and the other substituents are as described for Compound A)

At page 22, lines 25-31, please insert:

EXAMPLE 23: cyclo{Suc[1-(S)-(4-methylbenzen)sulfonylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein C-R[4]₄ has S-configuration, R[4]₄ is (4-methylbenzen)sulfonylamino and the other substituents are as described for Compound A)

At page 22, lines 30-31, please insert:

As starting compound the isomer of Compound A having S-configuration at the C-R[4]₄ is used.

At page 23, lines 2-6, please insert:

EXAMPLE 24: cyclo{Suc[1-(R)-(4-methylbenzen)sulfonylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of formula I wherein R[4]₄ is (4-methylbenzen)sulfonylamino and the other substituents are as described for Compound A)

At page 23, lines 11-15, please insert:

EXAMPLE 25: cyclo{Suc[1-(S)-(2-(4-morpholino)ethylamino)-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein C-R[4]₄ has S-configuration, R[4]₄ is 2-(4-morpholino)ethylamino and the other substituents are as described for Compound A)

At page 23, lines 26-29, please insert:

EXAMPLE 26: cyclo{Suc[1-(R)-(2-(4-morpholino)ethylamino)-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein R[4]₄ is 2-(4-morpholino)ethylamino and the other substituents are as described for Compound A)

At page 24, lines 2-5, please insert:

EXAMPLE 27: cyclo{Suc[1-(R)-(2-furylmethyl)amino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of formula I wherein R[4]₄ is (2-furylmethyl)amino and the other substituents are as described for Compound A)

At page 24, lines 15-18, please insert:

EXAMPLE 28: $\text{cyclo}\{\text{Suc}[1-(\text{R})-\text{c}[\text{i}]\text{yanomethylamino}]-\text{Trp}-\text{Phe}-[(\text{R})-\text{NH}-\text{CH}(\text{CH}_2-\text{C}_6\text{H}_5)-\text{CH}_2\text{NH}]\}$

compound of general formula I wherein $\text{R}[4]_4$ is $\text{c}[\text{i}]\text{yanomethylamino}$ and the other substituents are as described for Compound A)

At page 25, lines 1-2, please insert:

(compound of general formula I wherein $\text{R}[4]_4$ is 2-(4-morpholinoacetyl)amino and the other substituents are as described for Compound A)

At page 25, lines 16-20, please insert:

EXAMPLE 30: $\text{cyclo}\{\text{Suc}[1-(\text{S})-2-(4\text{-morpholinoacetyl})\text{amino}]-\text{Trp}-\text{Phe}-[(\text{R})-\text{NH}-\text{CH}(\text{CH}_2-\text{C}_6\text{H}_5)-\text{CH}_2\text{NH}]\}$

(compound of general formula I wherein $\text{R}[4]_4$ is 2-(4-morpholinoacetyl)amino, $\text{C}-\text{R}[4]_4$ has S-configuration and the other substituents are as described for Compound A)

At page 25, lines 28-32, please insert:

EXAMPLE 31: $\text{cyclo}\{\text{Suc}[1-(\text{S})-(2\text{-tetrazol-1-yl})\text{acetylamin}]\text{-Trp}-\text{Phe}-[(\text{R})-\text{NH}-\text{CH}(\text{CH}_2-\text{C}_6\text{H}_5)-\text{CH}_2\text{NH}]\}$

(compound of general formula I wherein $\text{C}-\text{R}[4]_4$ has S-configuration, $\text{R}[4]_4$ is (2-tetrazol-1-yl)acetylamin and the other substituents are as described for Compound A)

At page 26, lines 1-2, please insert:

As starting compound the isomer of compound A having S-configuration at $\text{C}-\text{R}[4]_4$ is used.

At page 26, lines 8-11, please insert:

EXAMPLE 32: $\text{cyclo}\{\text{Suc}[1-(\text{R})-(2\text{-tetrazol-1-yl)acetylamino}]\text{-Trp-Phe-}[(\text{R})\text{-NH-CH}(\text{CH}_2\text{-C}_6\text{H}_5)\text{-CH}_2\text{NH}]\}$

(compound of general formula I wherein $\text{R}[4]_4$ is (2-tetrazol-1-yl)acetylamino and the other substituents are as described for Compound A)

At page 26, lines 13-17, please insert:

EXAMPLE 33: $\text{cyclo}\{\text{Suc}[1-(\text{S})-(2-(5\text{-mercapto-tetrazol-1-yl)acetylamino}]\text{-Trp-Phe-}[(\text{R})\text{-NH-CH}(\text{CH}_2\text{-C}_6\text{H}_5)\text{-CH}_2\text{NH}]\}$

(compound of general formula I wherein C- $\text{R}[4]_4$ has S-configuration, $\text{R}[4]_4$ is (2-(5-mercapto-tetrazol-1-yl)acetylamino and the other substituents are as described for Compound A)

At page 26, lines 18-19, please insert:

As starting compound the isomer of Compound A having S-configuration at C- $\text{R}[4]_4$ is used.

At page 26, lines 25-29, please insert:

EXAMPLE 34: $\text{cyclo}\{\text{Suc}[1-(\text{R})-2-([1,2,4]\text{triazol-1-yl)acetylamino}]\text{-Trp-Phe-}[(\text{R})\text{-NH-CH}(\text{CH}_2\text{-C}_6\text{H}_5)\text{-CH}_2\text{NH}]\}$

(compound of general formula I wherein $\text{R}[4]_4$ is 2-([1,2,4]triazol-1-yl)acetylamino and the other substituents are as described for Compound A)

At page 27, lines 1-4, please insert:

EXAMPLE 35: $\text{cyclo}\{\text{Suc}[1-(\text{R})-(\text{furan-2-yl)carbonylamino}]\text{-Trp-Phe-}[(\text{R})\text{-NH-CH}(\text{CH}_2\text{-C}_6\text{H}_5)\text{-CH}_2\text{NH}]\}$

(compound of general formula I wherein $\text{R}[4]_4$ is (furan-2-yl)carbonylamino and the other substituents are as described for Compound A)

At page 27, lines 10-13, please insert:

EXAMPLE 36: cyclo{Suc[1-(R)-2-(thiophen-3-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein R[4]₄ is 2-(thiophen-3-yl)acetylamino and the other substituents are as described for Compound A)

At page 27, lines 18-21, please insert:

EXAMPLE 37: cyclo{Suc[1-(R)-(4-morpholino)carbonylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein R[4]₄ is (4-morpholino)carbonylamino and the other substituents are as described for Compound A)

At page 27, lines 29-31, bridging page 28 line 1, please insert:

EXAMPLE 38: cyclo{Suc[1-(R)-2-(4-hydroxy-piperidin-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein R[4]₄ is 2-(4-hydroxy-piperidin-1-yl)acetylamino and the other substituents are as described for Compound A)

At page 28, lines 6-10, please insert:

EXAMPLE 39: cyclo{Suc[1-(R)-2-(4-aminocarbonyl-piperidin-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}
[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein R[4]₄ is 2-(4-aminocarbonyl-piperidin-1-yl)acetylamino and the other substituents are as described for Compound A)

At page 28, lines 15-20, please insert:

EXAMPLE 40: cyclo{Suc[1-(R)-2-(3-hydroxy-pyrrolidin-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein R[4]₄ is 2-(3-hydroxy-pyrrolidin-1-yl)acetamino and the other substituents are as described for Compound A)

At page 29, lines 2-3, please insert:

(compound of general formula I wherein R[4]₄ is 2-(4-methyl-piperazin-1-yl)acetamino and the other substituents are as described for Compound A)

At page 29, lines 8-19 and 20-27, please insert:

EXAMPLE 43: cyclo{Suc[1-(R)-2-(4-methyl-piperazin-1-yl)carbonylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein R[4]₄ is 2-(4-methyl-piperazin-1-yl)carbonylamino and the other substituents are as described for Compound A)

A solution of 40 mg of compound A, obtained as described in EXAMPLE 1(a)-1(h), and 400 µl of DIPEA in THF (0.5 ml), is added, under nitrogen, to a solution of 27 mg of 4-methyl-1-piperazinocarbonyl chloride (prepared as described in C. Jorand-Lebrun et al., Synth. Commun. (1998), 28, 1189) in 0.5 ml of dichloromethane. The solution is stirred for 2 h at room temperature, dried and purified by HPLC (Method P7).

HPLC (Method A2): rt = 11.8 min.

MS: m/z = 707.2 (MH⁺).

EXAMPLE 44: cyclo{Suc[1-(R)-2-(4-aminosulfonyl-piperazin-1-yl)acetamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein R[4]₄ is 2-(4-aminosulfonyl-piperazin-1-yl)acetamino and the other substituents are as described for Compound A)

The compound was prepared according to EXAMPLE 29 but using as reagent 2-(4-aminosulfonyl-piperazin-1-yl)acetic acid.

HPLC (Method A2): t_r = 12.5 min.

MS: m/z = 786.3 (MH^+)

At page 29, lines 26-31, please insert:

EXAMPLE 45: cyclo{Suc[1-(R)-2-(1-oxo-thiomorpholin-4-yl)acetyl-amino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein R[4]₄ is 2-(1-oxo-thiomorpholin-4-yl)acetyl-amino and the other substituents are as described for Compound A)

At page 30, lines 5-9, please insert:

EXAMPLE 46: cyclo{Suc[1-(R)-2-(*trans*-4-hydroxy-cyclohexan-1-yl-amino)acetyl-amino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein R[4]₄ is 2-(*trans*-4-hydroxy-cyclohexan-1-yl-amino)acetyl-amino and the other substituents are as described for Compound A).

At page 30, lines 14-19, please insert:

EXAMPLE 47: cyclo{Suc[1-(4-morpholino)carbonyl]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein : X₁ = X₂ = X₃ = X₄ = -CO-NH-; R₁ = -CH₂-(indol-3-yl); R₂ = R₃ = -CH₂-C₆H₅; R[4]₄ = (4-morpholino)carbonyl; m = 0, f = 1; the C-R₁ and C-R₂ carbon atoms have S-configuration, while C-R₃ has R-configuration)

At page 31, lines 21-28, please insert:

To a solution of 200 mg of H-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂-NH-[2-(4-nitro-benzyloxycarbonyl)]-1-succinic acid in DMF (10 ml), under nitrogen at 0°C, PyBOP (160 mg) and TEA (108 μ l) were added; the solution was left under stirring at room temperature for 2 hours and thereafter sampled by HPLC. The solvent was evaporated and the residue was solved in ethylacetate. The organic phase was washed with

KHSO₄ aq. 5%, NaHCO₃ aq. 5%, brine and was dried on anhydrous sodium sulfate.

After filtration and evaporation of the solvent 180 mg of a residue were obtained.

At page 32, lines 4-9, please insert:

The compound cyclo{Suc[1-(4-nitro-benzyloxycarbonyl)-Trp-Phe-[(R)NH-CH(CH₂-C₆H₅)-CH₂-NH]} “slow moving” (50 mg) was added to a mixture 1:1 of water/isopropanole (2 ml) containing K₂CO₃ (17 mg). The reaction mixture was reacted for 24 h at room temperature, concentrated, diluted with water and extracted with ethylacetate to eliminate the unreacted product.

At page 32, lines 19-27, please insert:

The compound cyclo {Suc[1-(4-nitro-benzyloxycarbonyl)-Trp-Phe-[(R)-NH-CH₂-C₆H₅)-CH₂-NH]} “slow moving” (50 mg) was added to a mixture 1:1 of water/isopropanole (2 ml) containing K₂CO₃ (17 mg). The reaction mixture was extracted with ethylacetate to eliminate the unreacted product. The aqueous phase was acidified with HCl 1N up to the formation of a white suspension and extracted with ethylcetate. The organic phase of the second extraction was dried on anhydrous sodium sulfate and evaporated to give 18 mg of a white solid. The product was purified by preparative HPLC (Method P8).

At page 33, lines 13-17, please insert:

EXAMPLE 48: cyclo{Suc[1-(4-hydroxyethoxyethyl-piperazin-1-yl)carbonyl]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

(compound of general formula I wherein R₄ is (4-hydroxyethoxyethyl-piperazin-1-yl)carbonyl and the other substituents are as described in EXAMPLE 47)

HPLC (Method A2): rt =11.9 min.